## Masato Yoshikawa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5829486/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Discovery of 7-Oxo-2,4,5,7-tetrahydro-6 <i>H</i> -pyrazolo[3,4- <i>c</i> ]pyridine Derivatives as Potent, Orally Available, and Brain-Penetrating Receptor Interacting Protein 1 (RIP1) Kinase Inhibitors: Analysis of Structure–Kinetic Relationships. Journal of Medicinal Chemistry, 2018, 61, 2384-2409.	6.4	78
2	Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice. Scientific Reports, 2020, 10, 17081.	3.3	46
3	CETSA quantitatively verifies in vivo target engagement of novel RIPK1 inhibitors in various biospecimens. Scientific Reports, 2017, 7, 13000.	3.3	44
4	Discovery of Soticlestat, a Potent and Selective Inhibitor for Cholesterol 24-Hydroxylase (CH24H). Journal of Medicinal Chemistry, 2021, 64, 12228-12244.	6.4	25
5	Small-Scale Panel Comprising Diverse Gene Family Targets To Evaluate Compound Promiscuity. Chemical Research in Toxicology, 2020, 33, 154-161.	3.3	9
6	Discovery of Novel 3-Piperidinyl Pyridine Derivatives as Highly Potent and Selective Cholesterol 24-Hydroxylase (CH24H) Inhibitors. Journal of Medicinal Chemistry, 2022, 65, 3343-3358.	6.4	7
7	TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies, Cancer Research Communications, 2022, 2, 489-502.	1.7	5